We confirmed the induction of an immune response by immunohistochemistry using antibodies against HLA antigen (MHC-Class I) and against inflammatory cell markers in muscle biopsies from patients with TK2 mutations (P4 and in two consecutive biopsies from an additional patient not included in the array, P11 Table 1), a patient with MDS due to SUCLA2 mutations (P10, Table 1) and in disease controls (P5, P6 and P7 with large mtDNA deletions, Table 1). This evidence concerns the gene SUCLA2 and myelodysplastic syndrome.